We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00115570
Recruitment Status : Completed
First Posted : June 24, 2005
Last Update Posted : May 20, 2016
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Insulin-Dependent Drug: Insulin glulisine Drug: insulin lispro Drug: insulin glargine Drug: NPH insulin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 572 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Insulin Glulisine Compared With Insulin Lispro in Children and Adolescents With Type 1 Diabetes Mellitus: A 26 Week, Multicenter, Open, Parallel Clinical Trial
Study Start Date : April 2005
Actual Primary Completion Date : November 2006
Actual Study Completion Date : November 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Insulin Glulisine
Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks
Drug: Insulin glulisine
Subcutaneous injection
Other Name: apidra

Drug: insulin glargine
Subcutaneous injection once daily

Drug: NPH insulin
subcutaneous injection twice daily

Active Comparator: Insulin Lispro
Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks
Drug: insulin lispro
Subcutaneous injection

Drug: insulin glargine
Subcutaneous injection once daily

Drug: NPH insulin
subcutaneous injection twice daily

Primary Outcome Measures :
  1. Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint [ Time Frame: week 26 or last observed treatment ]

Secondary Outcome Measures :
  1. Change from Baseline in GHb at weeks 12 and 26 [ Time Frame: weeks 12 and 26 ]
  2. Change from Baseline in Self-monitored glucose parameters [ Time Frame: weeks 4, 12, 18, 26, and endpoint; ]
  3. Incidence of Symptomatic hypoglycemia [ Time Frame: first dose of study up to last dose ]
  4. Change from Baseline in basal insulin dose [ Time Frame: week 4, 12, 18, 26, and endpoint; ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Girls/boys, 4-17 years, inclusive;
  • Girls not yet of childbearing potential or, if sexually active, agree to use reliable medically accepted contraceptive measure during study;
  • Type 1 diabetes mellitus established in medical history: for example, but not limited to, clear signs of insulinopenia (polyuria, polydipsia, polyphagia, weight loss, ketonuria, ketoacidosis); or glutamic acid decarboxylase (GAD) antibody indicative of type 1 diabetes measured at any time before study; or requiring continuous insulin therapy from time of diagnosis;
  • Onset of diabetes at least 1 year prior to visit 1 (V1) of study;
  • Uninterrupted insulin therapy for at least 1 year before V1 of study;
  • At V1, on stable insulin regimen of either NPH or insulin glargine as basal insulin and willing to have multiple daily injections of insulin;
  • Glycated hemoglobin at V1 between ≥ 6.0 and ≤11.0 %;
  • Ability/willingness to do blood glucose monitoring using sponsor-provided glucometer and subject diary.

Exclusion Criteria:

  • Active proliferative diabetic retinopathy, defined by application of focal or panretinal photocoagulation or vitrectomy, 6 months before V1, or any other unstable/rapidly progressing retinopathy requiring surgical treatment (including laser photocoagulation) during study;
  • Diabetes other than type 1 diabetes mellitus;
  • Pregnancy (positive pregnancy blood test at V1) or breastfeeding;
  • Pancreatectomized subjects;
  • Subjects who have had pancreas and/or islet cell transplants;
  • Treatment with any anti-diabetic oral agent at any time from diabetes diagnosis;
  • Treatment with systemic corticosteroids in last month before V1;
  • Subjects on pump therapy during last 2 months before V1;
  • Subjects requiring excessively high doses of insulin ("resistant" patients), for example, but not limited to, subjects receiving over 150 IU per day;
  • Likelihood of needing treatment during study period with drugs not permitted by protocol
  • Treatment with any investigational drug in last month before V1;
  • History of primary seizure disorders;
  • History of severe hypoglycemic episode accompanied by seizure and/or coma or diabetic ketoacidosis leading to hospitalization, or to care in emergency ward, 3 months prior to V1;
  • History of hypoglycemia unawareness;
  • History of hypersensitivity to insulin or insulin analogs or any of the excipients in insulin glulisine formulation or any of the excipients in other study insulin preparations formulations;
  • Clinically relevant hepatic, neurologic, endocrine, active cancer, or other major systemic disease making implementation of protocol or interpretation of study results difficult and would, in the opinion of the investigator, preclude safe participation of subject in protocol;
  • History of cardiac abnormalities and/or cardiovascular disorders;
  • History of drug/alcohol abuse;
  • Impaired hepatic function shown by, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than twice the normal upper limit for age at V1;
  • Impaired renal function shown by, but not limited to, serum creatinine greater than 1.5 times upper limit for age at V1;
  • Non fasting triglyceride level of >500 mg/dL (5.7 mmol/L) at V1;
  • Parent/legally authorized representative unable to understand nature, scope, possible consequences of study;
  • Parent/legally authorized representative unable to read/write;
  • Subjects unlikely to comply with protocol, e.g. inability/unwillingness to participate in adequate training, uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing study;
  • Children/relatives of employee of sponsor or of sponsor representatives;
  • Children or relatives of investigator, any sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conduct of protocol;
  • Subjects who have previously been treated with insulin glulisine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00115570

Layout table for location information
United States, Pennsylvania
Childrens Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Dr Arethi PHILOTHEOU UCT Diabetes Clinical Trials Unit - Faculty of Health Sciences - South-Africa
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT00115570    
Other Study ID Numbers: EFC6096
HMR 1964
First Posted: June 24, 2005    Key Record Dates
Last Update Posted: May 20, 2016
Last Verified: May 2016
Keywords provided by Sanofi:
Diabetes,Insulin-Dependent, pediatric,rapid acting injection
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin, Globin Zinc
Insulin Glargine
Insulin Lispro
Insulin glulisine
Insulin, Isophane
Isophane Insulin, Human
Isophane insulin, beef
Hypoglycemic Agents
Physiological Effects of Drugs